TY - JOUR
T1 - Guide for Drug Selection During Pregnancy and Lactation
T2 - What Pharmacists Need to Know for Current Practice
AU - Griffin, Brooke L.
AU - Stone, Rebecca H.
AU - El-Ibiary, Shareen Y.
AU - Westberg, Sarah
AU - Shealy, Kayce
AU - Forinash, Alicia
AU - Yancey, Abigail
AU - Vest, Kathleen
AU - Karaoui, Lamis R.
AU - Rafie, Sally
AU - Horlen, Cheryl
AU - Lodise, Nicole
AU - Cieri-Hutcherson, Nicole
AU - McBane, Sarah
AU - Simonyan, Anahit
PY - 2018/8/1
Y1 - 2018/8/1
N2 - Objective: To provide guidance for clinicians on risk assessment of medication use during pregnancy and lactation. Data Sources: Authors completed PubMed searches to identify articles focused on the use of medications in pregnancy, including fetal development, drug transfer across the placenta, trimester exposure, chronic conditions in pregnancy, medications in lactation, and lactation and chronic disease. Study Selection and Data Extraction: Articles were reviewed to provide overall guidance to medication selection during pregnancy. The following information was reviewed: medication use in pregnancy, including fetal development, drug transfer across the placenta, trimester exposure, chronic conditions in pregnancy, medications in lactation, and lactation and chronic disease. Data Synthesis: This article will provide an overview of medication safety considerations during pregnancy and lactation. Information was interpreted to help clinicians predict the potential risk and benefit in each patient to make an evidence-based decision. The article concludes with guidance on risk assessment and how pharmacists may support fellow health care providers and their patients when considering medication use. Conclusions: Information about the effects of medication use during reproductive periods is limited. With the removal of the Food and Drug Administration pregnancy categories, clinicians will be relying on pharmacists to aid in the appropriate selection of therapies for patients. It is critical that pharmacists keep abreast of resources available and be able to assess data to help prescribers and their patients.
AB - Objective: To provide guidance for clinicians on risk assessment of medication use during pregnancy and lactation. Data Sources: Authors completed PubMed searches to identify articles focused on the use of medications in pregnancy, including fetal development, drug transfer across the placenta, trimester exposure, chronic conditions in pregnancy, medications in lactation, and lactation and chronic disease. Study Selection and Data Extraction: Articles were reviewed to provide overall guidance to medication selection during pregnancy. The following information was reviewed: medication use in pregnancy, including fetal development, drug transfer across the placenta, trimester exposure, chronic conditions in pregnancy, medications in lactation, and lactation and chronic disease. Data Synthesis: This article will provide an overview of medication safety considerations during pregnancy and lactation. Information was interpreted to help clinicians predict the potential risk and benefit in each patient to make an evidence-based decision. The article concludes with guidance on risk assessment and how pharmacists may support fellow health care providers and their patients when considering medication use. Conclusions: Information about the effects of medication use during reproductive periods is limited. With the removal of the Food and Drug Administration pregnancy categories, clinicians will be relying on pharmacists to aid in the appropriate selection of therapies for patients. It is critical that pharmacists keep abreast of resources available and be able to assess data to help prescribers and their patients.
KW - lactation/drug effects
KW - pregnancy/drug effects
KW - women’s health
UR - http://www.scopus.com/inward/record.url?scp=85044021997&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044021997&partnerID=8YFLogxK
U2 - 10.1177/1060028018764447
DO - 10.1177/1060028018764447
M3 - Review article
C2 - 29519141
AN - SCOPUS:85044021997
VL - 52
SP - 810
EP - 818
JO - Annals of Pharmacotherapy
JF - Annals of Pharmacotherapy
SN - 1060-0280
IS - 8
ER -